Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...
Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and ...
A study found Indian generics sold in the US between 2009-2018 linked to a 54% higher risk of serious side effects compared ...
India’s Contract Development and Manufacturing Organization (CDMO) market is witnessing a strong growth trajectory driven by ...
Dilip Shanghvi, chairman of India's largest drugmaker Sun Pharma, told an industry gathering last week that his company sells ...
The USFDA has established an office in India to oversee the number of Indian manufacturers qualified to supply generic ...
India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics, a U.S.-based immunotherapy and ...
India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...
The Indian pharmaceutical exports ranked 11th globally in value terms in the year 2023 and accounted for 3% of the total ...
The Print on MSN2d
Top pharma alliance refutes ‘ill-researched’ US study linking Indian generics to higher adverse eventsIndian Pharmaceutical Alliance says the study relies on FDA Adverse Event Reporting System data, which captures link between ...
Indian pharmaceutical CDMOs are anticipated to encounter minimal disruptions from the proposed US tariffs of 10-25 per cent.
March 10 (Reuters) - India's Sun Pharmaceutical Industries (SUN.NS), opens new tab said on Monday it will acquire Checkpoint Therapeutics (CKPT.O), opens new tab, a U.S.-based immunotherapy and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback